CEO, BioEclipse Therapeutics
Scientist and entrepreneur, Dr. Pamela Contag founded four venture-backed start-up companies; Dr. Contag founded Xenogen Corporation in 1995 and took Xenogen public in 2004 with M&A to Caliper Life Sciences in 2006. Xenogen Corporation was listed as one of the “Top 25 Young Businesses” by Fortune Small Business and received the R&D 100 award for achievements in Physics; She was the Chairman and CEO of Cobalt Biofuels from 2005-2008. In 2008 Cobalt was named one of the top 20 Cleantech Companies and in 2009-2014 was consistently one of the top 100 Cleantech Companies.; Cygnet Biofuels, a company that consults and develops platforms in biomass and biofuels; and BioEclipse Therapeutics (fka ConcentRx), a novel a cell-based immune therapy company for oncology indications. Pamela was named one of the “Top 25 Women in Small Business” by Fortune magazine. She was also awarded the Northstar Award from Springboard Enterprises in 2008 and the Cleantech Innovator of the year in 2011 from Astia.
Dr. Contag has held board positions, public, private and not-for-profit sectors. Dr. Contag was a consulting Professor at Stanford School of Medicine in the Department of Pediatrics from 1999-2012, and was appointed to the Deans Advisory Board for Bloomberg School of Public Health and served from 1999-2005. She was appointed to the USDA/DOE Biomass Technology Advisory Committee and served from 2009 to 2015 and was also appointed by the White House to the Founding Board of The StartUp America Partnership, an organization envisioned by the Case and Kauffman Foundation and The White House to identify, encourage and celebrate all entrepreneurs and served from 2011 to 2014. She has been a Trustee of the Molecular Sciences Institute (MSI), a nonprofit research institute, since 2011 and Chairman of the Board of Trustees since 2013. She has served on the Springboard Enterprises National Board of Directors since 2004. She was a Board Director of Delcath (Nasdaq) from 2008-2011 and a Director on the Marrone BioInnovations (Nasdaq) board from 2012-2016. Experienced in Governance and Compensation. She also held positions on product, finance and audit committees.
With more than 25 years of microbiology research experience, Dr. Contag is widely published in the field of Microbiology and Optical imaging and has over 35 patents in Biotechnology. Dr. Contag received her Ph.D. in Microbiology at the University of Minnesota Medical School in 1989 studying Microbial Physiology and Genetics (for Alternative Fuels) and completed her Postdoctoral Training at Stanford University School of Medicine in 1993 specializing in “Host/Pathogen Interactions”.